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Background: Cardiomyopathy is reported in Duchenne and Becker muscle dystrophy patients and female carriers.
Brain Natriuretic peptide (BNP) is a hormone produced mainly by ventricular cardiomyocytes and its production is
up regulated in reaction to increased wall stretching. N-terminal-proBNP (NT-proBNP) has been shown to be a
robust laboratory parameter to diagnose and monitor cardiac failure, and it may be helpful to screen for asymptomatic
left ventricular dysfunction. Therefore we tested whether NT-proBNP can distinguish patients with Duchenne or Becker
muscular dystrophy patients and carriers of a dystrophin mutation with a dilated cardiomyopathy from those without.
Methods: In a cohort of Duchenne and Becker muscle dystrophy patients (n = 143) and carriers (n = 219) NT-proBNP
was measured, and echocardiography was performed to diagnose dilated cardiomyopathy (DCM).
Results: In total sixty-one patients (17%) fulfilled the criteria for DCM, whereas 283 patients (78%) had an elevated
NT-pro BNP. The sensitivity of NT-proBNP for DCM in patients or carriers was 85%, the specificity 23%, area under the
ROC-curve = 0.56. In the specified subgroups there was also no association.
Conclusion: Measurement of NT-pro BNP in patients suffering from Duchenne or Becker muscular dystrophy and
carriers does not distinguish between those with and without dilated cardiomyopathy.
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It is well known that the heart is involved in Duchenne
muscular dystrophy (DMD) and Becker muscular dys-
trophy (BMD), both caused by mutations in the dys-
trophin gene on the short arm of the X-chromosome
(Xp21). In BMD the dystrophin function is altered in a
variable way mostly due to an “in-frame” mutation but
nearly always present. In DMD dystrophin is absent
(<5%) due to mainly an “out-of-frame”-mutation. Pa-
tients with DMD are found to have dilated cardiomyop-
athy at a median age of onset of 16.8 (range 15–18.7),
whereas in BMD median onset is 30.4 (range 23.8-37.0)* Correspondence: a.j.kooi@amc.uva.nl
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distribution, and reproduction in any medium[1]. Nearly 72% of DMD patients above the age of 18
years have echocardiographic evidence of a dilated left
ventricle and a reduced ejection fraction (< 45%) [2]. We
and others found a frequency of DCM in BMD patients
ranging from 33-49%, which was associated with the
duration of the disease [3,4]. In BMD, cardiac involve-
ment can occur in the absence of significant muscle
weakness [5]. Carriers of a dystrophin-gene mutation
are also at risk of cardiac involvement, often in the ab-
sence of muscle weakness [6,7]. In various study popula-
tions the incidence of dilated cardiomyopathy (DCM)
among DMD carriers varied between 7% to 9%, and
among BMD carriers from 0% to 13% [6-8]. Brain Natri-
uretic peptide (BNP) is a hormone produced mainly by
myocytes of the cardiac ventricular wall. Its production
is upregulated in reaction to stretching of the wall as oc-
curs in DCM. It is formed by the splicing of proBNP intoioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in a 1:1 ratio. Since NT-proBNP is more stable than BNP
it is widely used as a marker. In a recent paper about the
use of natriuretic peptide (NP) levels, among them BNP
and NT-proBNP, in clinical practice Maisel et al. report
that the role of NP levels in clinical practice is evolving
rapidly and has been incorporated into most national and
international cardiovascular guidelines for heart failure
[9]. NP levels are found to be quantitative plasma bio-
markers of heart failure (HF), are accurate in the diagnosis
of HF, can accelerate accurate diagnosis of heart failure
presenting in primary care, and may be helpful to screen
for asymptomatic left ventricular dysfunction in high-risk
patients. In DMD patients raised concentrations of BNP
associated with heart failure have also been found [10,11].
Because DCM is considered a severe complication of
DMD or BMD and may arise unnoticed in asymptomatic
carriers we investigated the prevalence of DCM and the
levels of NT-proBNP. A cross-sectional study among pa-
tients and carriers was performed in order to address the
question whether NT-proBNP might be a marker of the
presence of DCM in dystrophinopathies.
Methods
Patients
Between January 2002 and February 2005 a convenience
sample of patients with DMD, BMD and carriers of
these disorders were asked to participate. Since the Clin-
ical Genetic Centre of the University Medical Centre
Leiden, the Netherlands, is the referral centre for DNA
testing for mutations in the dystrophin gene their data-
base was scrutinized for eligible patients. Subsequently,
the treating physicians were asked to contact these pa-
tients. Patients were also informed through the patients’
support association (‘Vereniging Spierziekten Nederland’).
Inclusion criteria were the following: age 8 to 70 years,
and a definite diagnosis of dystrophinopathy. The diagno-
sis was considered definite when muscle biopsy demon-
strated absence of dystrophin on immunohistochemical
staining (DMD), or on Western Blot, or when DNA ana-
lysis demonstrated the presence of a mutation in the dys-
trophin gene (DMD, BMD and carriers). Carriers could
also be considered definite when pedigree analysis indi-
cated they were obligate carriers or linkage analysis re-
vealed a chance of more than 99% indicating that they
were obligate carriers. All were assigned a functional
grade based on a scale described by Brooke et al. in order
to assess disability due to skeletal muscle involvement
[12]. Patients or carriers were considered functionally
symptomatic when they experienced disability due to
muscle weakness in the upper or lower extremities or
both, leading to a Brooke score > 1 (not being able to
climb stairs without aid of the railing or worse, and/or ab-
duct the arms in a full circle until they touch above thehead or worse). Patients or carriers with DCM without
disability due to skeletal muscle weakness were not con-
sidered functionally symptomatic. Patients or carriers
who recently had had a cardiovascular event, such as
myocardial infarction or unstable angina, or who had
undergone a major surgical intervention were excluded.
Investigations
The patients were invited to the out-patient department
of the Academic Medical Centre, Amsterdam, the
Netherlands. A standardised questionnaire was applied
for symptoms suggestive of heart failure such as dys-
pnoea on exertion, orthopnoea, nocturia, chest pain, pal-
pitations, dizziness or collapse and decrease of appetite.
The use of medication was registered. The functional
scale designed by Brooke was assessed for both upper
and lower extremities [12]. The slow vital capacity, mea-
sured with a hand held spirometer, was registered as a
percentage of the normal value related to age, height
and gender. Blood pressure, height and weight were
measured. The Body Surface Area (BSA) and Body Mass
Index (BMI) were calculated. Obesity was defined as a
BMI > 30.
All patients and carriers were subjected to echocardi-
ography using a Vivid 5 GE echocardiograph equipped
with a 5 MHz transducer (LD). Parameters measured
were: Left Ventricle End Diastolic Diameter (LVEDD),
Left Ventricle End Systolic Diameter (LVESD), both in
parasternal long axis projection. Global Left Ventricular
Function (LVF) was judged as good, fair, or poor by an
experienced cardiologist (L.D.) [13,14]. The Fractional
Shortening Index was calculated (FSI) as follows:
((LVEDD-LVESD)/LVEDD)*100%. The LVEDD was
corrected for age and body surface area [15]. DCM was
defined as an enlarged left ventricle with a global left
ventricle dysfunction or fractional shortening of 28% or
less, according to guidelines of the World Health
Organization/International Society and Federation of
Cardiology Task Force [16]. Patients were considered to
suffer from chronic heart failure (CHF) when they had
symptoms of heart failure, an abnormal ECG and a FSI
less than 45%, according tot the guidelines of the task
force for the diagnosis and treatment of chronic heart
failure of the European Society of Cardiology [17].
Peripheral blood was drawn by venapuncture after at
least one-hour rest during the interview for N-terminal
pro-brain Natriuretic peptide (NT-proBNP) analysis using
Enzyme Immunoassay, Biomedica Medizinprodukte
GmbH & CO KG, Vienna, Austria. According to the
manufacturer, NT-proBNP levels of less than 350 pmol/L
were considered as normal. Independent investigators
blinded for the results of the other parameters performed
electrocardiography, echocardiography, and laboratory
investigations.
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Demographic and clinical characteristics of the study
group were summarized using descriptive statistics. Differ-
ences in proportions, medians and means were analysed
using the χ2 test, Mann Whitney test, Fisher’s exact test, a
two-group t-test or a Mann–Whitney U test, when appro-
priate. The diagnostic ability of NT-proBNP was ex-
pressed in terms of sensitivity, specificity, and area under
the ROC curve (AUC). In both the total study group and
separate subgroups we analysed the impact of continuous
and dichotomous NT-proBNP levels on DCM using
multivariate logistic regression, adjusted for disease dur-
ation, weakness or complaints suggestive of heart failure.
Effect size was expressed in odds ratios (OR).
With a χ2-test we additionally analysed the association
between an elevated NT-proBNP and the separate param-
eters of DCM, viz. an enlarged LVEDD, a decreased FSI or
global left ventricle hypokinesia at 2D echocardiography.
We also compared the level of NT-proBNP in those re-
ceiving medication versus those who did not with a χ2-
test. In addition we analysed the association between
diastolic dysfunction and NT-proBNP, DCM and symp-
toms of heart failure with a χ2-test. All analyses were done
with SPSS 16.0 for Windows (SPSS Inc. Illinois, USA).
When subgroups were compared, they were formed on the
basis of their diagnosis (see above). Carriers were further
classified by whether they were functionally symptomatic,
as described above, or asymptomatic. Statistical uncer-
tainty was expressed in 95% confidence intervals (C.I).
Informed consent and funding
The study conforms with the principles outlined in the
Declaration of Helsinki and had the approval of theTable 1 Demographic features and clinical characteristics of 3
DMD BMD
n 55 88
Median age (yr) (range) 12 (8–44) 30 (8–5
Median disease duration (yr) (range) 10 (4–41) 20 (1–5
Median vital capacity (%) (range) 52 (14–84) 88 (18–1
Median diastolic blood pressure (mmHg) (range) 66 (44–87) 76 (48–1
Hypertension+ 2 (4%) 26 (30%
Wheelchair bound 34 (62%) 12 (14%
Treatment# 3 (6%) 17 (19%
Any Symptom CHF* 6 (11%) 15 (17%
Obesity§ 0 5 (6%
#Treatment: percentage of persons receiving medication including beta-blockers, diure
type-1 inhibitors (AT-1-inhibitors).
*Symptoms of CHF: percentage with any symptom of cardiac heart failure (CHF) like
+Hypertension: blood pressure higher than 90 mmHg diastolic or 140 mmHg systol
§Obesity: Body Mass Index >30.
na not applicable.Medical Ethical Committee of the Academic Medical
Centre, Amsterdam, The Netherlands. All included pa-
tients gave informed consent for participation in the
study. When an included patient was under the age of
18, informed consent was also given by a parent or
guardian.
The work was supported by the Prinses Beatrix Fonds,
The Hague, The Netherlands.
The authors are solely responsible for the design and
conduct of this study, all study analyses and drafting and
editing of the paper.
Results
The data of 362 out of 404 eligible patients and carriers
were available for complete analysis. Thirty-nine patients/
carriers were excluded because of missing NT-proBNP
data (n = 30), missing echocardiography variables (n = 9)
or the body surface area could not be calculated due to
deformities (n = 3). A DNA mutation in the dystrophin-
gene was present in 71% of the included patients or car-
riers (85% DMD, 72% BMD and 77% carriers). In the
remainder diagnosis was established by immunohisto-
chemical or –biochemical investigation of a muscle bi-
opsy in DMD or BMD patients (13%) or by pedigree or
linkage analysis in carriers (16%).
Demographic features and clinical characteristics of
the various subgroups are shown in Table 1. Complaints
suggestive of cardiac failure such as dyspnea on exertion,
orthopnoea, nocturia, chest pain, palpitations were
present in 11% of DMD patients, 17% of BMD patients,
and 27% of the carriers, respectively. The main symp-
tom, viz. exertional dyspnoea: was found in 2% in DMD













10 130 4 75
9) 56 (27–69) 44 (8–68) 47 (22–64) 44 (16–72)
2) 10 (0–36) na 26 (7–44) na
61) 87 (69–125) 106 (61–203) 115 (41–122) 108 (61–166)
12) 82 (67–99) 83 (56–116) 77 (73–90) 77 (60–108)
) 7 (70%) 54 (42%) 1 (25%) 23 (31%)
) 0% na 0% na
) 3 (30%) 14 (11%) 1 (25%) 4 (5%)
) 7 (70%) 30 (23%) 3 (75%) 19 (25%)
) 6 (30%) 19 (16%) 1 (25%) 9 (13%)
tics, Angiotensin Converting Enzyme-inhibitors (ACE-inhibitors) or Angiotensin II
nocturia, orthopnea, exercise induced dyspnoea, chest pain or dizziness.
ic.













LVEDD (mm, range) 42 (35–66) 54 (33–77) 52 (43–64) 50 (40–69) 51.5 (42–58) 49 (39–78)
FSI (%, range) 33 (5–48) 30 (3–48) 35 (14–48) 33 (13–55) 32 (24–40) 34 (5–52)
LVF Dysfunction§ 20% 34% 14% 10% 0% 3%
LVEDD Left Ventricle End Diastolic Diameter, FSI Factional shortening Index, LVF Left Ventricular Function.
§ LVF dysfunction is any function less than good.




NT-proBNP Elevated 52 231 283
Normal 9 70 79
61 301 362
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asymptomatic due to the lack of skeletal muscle weak-
ness. ACE inhibitors, β-blockers or diuretics were used
by 42 (12%) of patients or carriers. Eight (14%) DMD pa-
tients received corticosteroids. None of the patients or
carriers had complaints or a history of coronary artery
disease. Obesity was present in 3% (5/143) of the DMD
or BMD patients and in 16% (35/219) of the carriers
(overall 40/362, 11%). Four DMD patients, three BMD
patients and none of the carriers (7/362, 2%) had ventila-
tory support.
In total thirty-three (9%) patients/carriers met the cri-
teria for chronic heart failure. The echocardiographic
variables are shown in Table 2. In total 283 patients/car-
riers (78%) had an elevated NT-pro BNP. The point-
prevalences of patients or carriers fulfilling the defined
criteria for chronic heart failure (CHF) or DCM in the
DMD patients were 6% and 16% (3/55 and 9/55), re-
spectively, in the BMD patients 14% and 32% (12/88 and
28/88), respectively and in the carriers 8% and 11% (18/
219 and 24/219), respectively. Overall, DCM was present
in 61 out of 362, 17%. No significant difference in the
frequencies of the presence of DCM between the groups
with and without an elevated NT-proBNP was found
(52/283 vs. 9/79 i.e.:18% vs. 11%, p 0.14) (Table 3). There
was also no significant difference in the frequencies of
chronic heart failure between the groups with and without
an elevated NT-proBNP (11% vs 9%, p 0.06 Chi-square).
The distribution of the NT-proBNP concentration among
the different disease categories is shown in Figure 1. Only
in DMD patients the median NT-proBNP level is signifi-
cantly higher among patients with DCM (440 vs. 840
pmol/L, p 0.01) (Table 4).
The sensitivity (52/61) rate and specificity (70/301)
rate of NT-proBNP for the presence of DCM in the
whole cohort were 85% and 23%, respectively. The area
under the ROC curve (AUC) was 0.56 (95% C.I.: 0.48-
0.65) (Figure 2). The sensitivity (30/33) and specificity
(76/329) rates of NT-proBNP for the presence of
chronic heart failure were 91% and 23%, respectively.
The AUC was 0.58 (95% C.I.: 0.49 – 0.68).
No significant association between elevated NT-
proBNP and DCM was found in the subgroups, i.e.,
DMD, BMD, asymptomatic or symptomatic carriers(data not shown) When NT-proBNP level was entered
as a dichotomous independent variable (elevated or not)
into a logistic regression model (adjusted for disease
duration, weakness, treatment or complaints suggestive
of heart failure) no statistical significant associations
could be demonstrated. In DMD patients: OR = 2.16
(95% C.I. 0.21-22.79, p 0.52); in BMD patients: OR = 0.92
(95% C.I. 0.30 -2.83, p 0.89); in carriers: OR = 4.84 (95%
C.I. 0.51-31.58, p 0.19). In the total study group the OR
was 1.49 (95% C.I. 0.67-3.34, p 0.33). When NT-proBNP
concentration was entered as a continuous variable into
the model, the parameter did not explain the presence of
DCM in the total study group (OR = 1.87, 95% C.I. 0.68-
5.13, p 0.23). Also, NT-proBNP was not associated with
the presence of DCM in BMD patients separately (OR = 1.9
(95% C.I. 0.40-9.11, p 0.42) or carriers (OR = 2.26, 95% C.I.
0.40-9.75, p 0.40). In DMD patients the regression model
could not be fitted statistically because of the low inci-
dence of DCM in this subgroup.
Neither could we demonstrate a significant difference
in the frequencies of an elevated NT-pro BNP between
patients or carriers with and without an LVEDD exceed-
ing the maximal LVEDD corrected for age and body sur-
face area (82% vs. 76%) (p 0.22), with or without a
fractional shortening index less than 28% (82% vs. 77%,
p 0.25) or with or without global left ventricle hypo-
kinesia at 2D echocardiography (85% vs. 77%, p 0.22).
The frequency of an elevated (> 350 pmol/L) NT-
proBNP among patients or carriers receiving medica-
tion was 39 (93%) compared to 244 (76%) among
those without medication (p = 0.01). The level of NT-
proBNP was significantly higher in those receiving medi-
cation compared to those without (800 vs 590 pmol/L,
p < 0.001).
Figure 1 Distribution of concentration NT-proBNP shows no
difference amongst the separate disease categories.
Figure 2 Receiver Operating Curve of NT-proBNP for DCM in
the whole cohort.
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In this cross-sectional study encompassing a large num-
ber of DMD and BMD patients and carriers the overall
point prevalence of dilated cardiomyopathy was 17%.
Across the whole group, there was no significant differ-
ence in the frequency of elevated NT-proBNP levels be-
tween individuals with or without dilated cardiomyopathy.
There was no relation between an elevated NT-proBNP
and DCM when corrected for disease duration, treatment
any weakness or complaints of heart failure. Only in
DMD patients with DCM the median NT-proBNP level
was higher than in DMD patients without DCM. How-
ever, it was impossible to statistically correct for disease
duration, treatment, any weakness or complaints of heart
failure with a logistic regression analysis since the model
did not fit. The ROC- analysis did not show a more dis-
criminatory threshold. Our goal was to assess whether
NT-proBNP might be a marker of the presence of DCM
in dystrophinopathies and the study showed that the over-
all accuracy of the NT-proBNP test to diagnose dilated
cardiomyopathy was poor.
It is of note, that complaints suggestive of cardiac fail-




DMD (range) 440 (110–840) 840 (170–1360) 0.01
BMD median (range) 510 (100–1180) 580 (160–3170) ns
Carrier DMD (range) 660 (140–1530) 665 (400–1380) ns
Carrier BMD (range) 600 (130–1710) 845 (350–1340) ns
Carrier overall (range) 640 (130–1710) 665 (350–1380) ns
§Mann–Whitney test.often found in the carriers of dystrophin mutations (all
carriers: 59/219, 27%) as compared to patients with
DMD (11%) or BMD (17%). There may be several expla-
nations for this counterintuitive observation. First, there
is no consensus about the validity and reliability of
symptoms indicating chronic heart failure [17]. Second,
the differences in the frequency might be explained by
the interaction between physical capabilities and the se-
verity of the loss of function of dystrophin and the in-
verse relationship between these two elements. None of
the carriers were wheelchair bound so the cohort of car-
riers seems to be more capable of performing exercise-
related activities than BMD and DMD patients of whom
14% and 62% respectively were wheelchair bound. In line
with that BMD patients who have intermediate function
of dystrophin as compared to DMD and carriers have
more complaints of heart failure than do DMD patients.
Third, muscle weakness might lead to higher demands
on the cardiac system in patients who remain ambula-
tory and consequently leads earlier to complaints of
heart failure. Fourth, the higher frequency of obesity in
the cohort of carriers (16% in carriers vs. 3% in patients)
is a confounding factor. However, the low percentage of
obesity found in patients could be an underestimation
because patients have a variable level of muscle atrophy
which diminishes the total body mass.
The frequency of DCM was 11% in carriers, as com-
pared to 16% in DMD and 32% in BMD. Others have
found prevalences up to nearly 72% of DMD patients
above the age of 18 years [2]. The relatively low preva-
lence of DCM in our DMD patients may be explained
by the fact that 80% of the patients was below the age of
20, and by our strict definition of DCM where others
used less stringent criteria, i.e., echocardiographic evi-
dence of a dilated left ventricle and a reduced ejection
fraction (< 45%) [2].
BNP has been previously studied as marker for left
ventricle dysfunction in patients with Duchenne and
Becker muscular dystrophy and in carriers [10,18-20].
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BNP and the shortening fraction of the left ventricle in
63 DMD patients [10]. When the shortening fraction
was found to be below 15% the BNP level rose exponen-
tially. Thereupon the authors concluded that BNP was a
marker for a severely affected ejection fraction, but not a
sensitive marker for early left ventricle dysfunction. This
was confirmed by Demachi et al. and Mohyuddin et al.
[19,21]. Demachi compared 31 patients with DMD/
BMD with 20 patients with idiopathic dilated cardiomy-
opathy. The former had lower levels of BNP than the lat-
ter, especially when the left ventricle ejection fraction
was markedly diminished. They hypothesised that the
difference may well be explained by the lesser mechan-
ical strain of the left ventricular myocytes and epicardial
fibrosis in DMD/BMD and the reduced physical activity
since all patients in the study were wheelchair
dependent. A linear correlation between BNP and frac-
tional shortening or left ventricle diameter was found in
15 DMD carriers described by Adachi [20]. In 65% of
the carriers with an enlarged left ventricle and in 50% of
the carriers with decreased fractional shortening an ele-
vated BNP was present.
In contrast to the afore-mentioned publications we ad-
hered to a strict definition of DCM according to the
guidelines of the World Health Organisation/Inter-
national Society and Federation of Cardiology Task
Force, namely an enlarged LVEDD corrected for weight
and age together with a global left ventricle dysfunc-
tion or a fractional shortening index (FSI) of less than
28%, according to guidelines of the World Health Or-
ganisation/International Society and Federation of
Cardiology Task Force [16]. The relative low inci-
dence of DCM might explain why NT-proBNP failed
to discriminate between DCM negative and DCM
positive patients/carriers when corrected for age, weak-
ness, treatment and complaints in a logistic regression
analysis.
Treatment of left ventricle dysfunction in muscular
dystrophies is studied in DMD patients, not in carriers.
In DMD patients dysfunction of the left ventricle func-
tion can be influenced by treatment [22-25]. In trials on
patients with acute or chronic heart failure on the basis
of other diseases than a dystrophinopathy, it has been
shown that NT-proBNP decreases if treatment of heart
failure due to left ventricle dysfunction is successful
[26,27]. Therefore it might be expected that treatment
with ACE-inhibitors with or without beta-blockers irre-
spective of the indication of treatment in DMD or BMD
can also result in a decreased level of natriuretic pep-
tides. In the Netherlands dystrophinopathy patients and
carriers tend to be treated since the frequency of treated
patients or carriers was significantly higher in those with
DCM compared to those without DCM. However, itseems unlikely that treatment has interfered with the
diagnostic ability of NT-proBNP for DCM since patients
or carriers on this medication had more often an ele-
vated NT-proBNP and a higher mean NT-proBNP than
those without DCM.
NT-proBNP was found to be significantly correlated
with depressed LV function on echocardiography in a
cohort of 28 wheelchair dependent DMD patients who
were on a (non)invasive mechanical ventilator [11]. In
contrast, our cohort was more heterogeneous showing
differences in disease severity (2% on mechanical ventila-
tion and 13% wheelchair dependent), age and co-
morbidity. However, neither in the whole cohort nor in
the separate subgroups an elevated NT-proBNP was as-
sociated with DCM. Given the relatively high sensitivity
of NT-proBNP for DCM it might be considered as a
screening tool but compared to the non-invasive echo-
cardiogram, NT-proBNP does not outperform the echo-
cardiogram as a screening tool. The heterogeneity of the
cohort, the lack of association when adjusted for treat-
ment, weakness or disease duration strengthen the con-
clusion that measurement of NT-pro BNP in patients
suffering from Duchenne or Becker muscular dystrophy
or carriers is not helpful to diagnose dilated cardiomyop-
athy in any phase of the disease.
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